Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy

Hye Jin Choi, Jeong Won Lee, Beodeul Kang, Si Young Song, Jong Doo Lee, and Jae-Hoon Lee

Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul; Departments of Nuclear Medicine and Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Purpose: We investigated the prognostic role of volume-based parameters measured on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) scans in patients with locally advanced pancreatic cancer (LAPC) treated with chemoradiation therapy (CRT). Materials and Methods: We enrolled 60 patients with LAPC who underwent FDG PET/CT before CRT. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of primary pancreatic cancers were measured on FDG PET/CT scans. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumors. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard models were used to determine independent prognostic factors.

Results: The progression-free survival (PFS), locoregional progression-free survival (LRPFS), and overall survival (OS) for this population were 6.2, 10.9, and 13.2 months, respectively. The overall treatment response rate was 16.7% at 4 weeks after CRT, and the disease control rate (DCR) was 80.0%. DCR was significantly higher in patients with low SUVmax, MTV, or TLG, and showed strong correlation with longer survival times. On univariate analysis, MTV and TLG were significant prognostic factors for PFS, LRPFS, and OS, together with pre-CRT and post-CRT CA19-9 levels. Multivariate analyses demonstrated that MTV together with the pre-CRT CA19-9 level were independent prognostic factors for PFS, LRPFS, and OS, as was TLG for LRPFS and OS. Conclusion: MTV and the pre-CRT CA19-9 level provided independent prognostic information in patients with LAPC treated with CRT. Volume-based PET/CT parameters may be useful in identifying which subgroup of patients would benefit from radiation therapy as a part of CRT.

Key Words: Locally advanced pancreatic cancer, FDG, PET, metabolic tumor volume, prognosis

INTRODUCTION

Pancreatic cancer is one of the most lethal cancers. According to a recent report, about 15% of patients with pancreatic cancer survived 1 year after diagnosis, and...
fewer than 5% survived 5 years. Only 20% of patients with pancreatic cancer have resectable tumors at the time of presentation, with a long-term survival rate of approximately 20%. A much higher percentage (40% to 45%) of patients present with metastatic disease and have a median survival of only 3–6 months.

Patients with locally advanced pancreatic cancer (LAPC) are an intermediate favorable prognostic group and are associated with a median survival of 6–10 months. Treatment for LAPC has evolved to consist of chemotherapy alone or in combination with radiotherapy. Although chemoradiation therapy (CRT) remains a treatment option, only a small number of randomized clinical trials have reported improved survival outcomes, and many have argued the value of radiation therapy (RT) for the subset of patients with LAPC due to the high rate of distant metastasis and subsequent poor survival outcomes even after successful local control.

F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) is now widely used to assess many different types of malignancy, and several studies have demonstrated an important role of FDG PET/CT in staging, detecting postoperative recurrence, and evaluating treatment response in patients with pancreatic cancer. Other studies have shown that the standardized uptake value (SUV) of primary pancreatic cancer lesions measured on pretreatment FDG PET/CT scans can help to predict survival outcomes in patients with pancreatic cancer. Recently, PET/CT-based volumetric imaging parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), have also been shown to be useful prognostic indicators for various neoplasms. However, few studies have evaluated volumetric parameters as prognostic factors in patients with LAPC. Moreover, while investigators have established prognostic factors for pancreatic cancer, data regarding LAPC are limited. The objective of this study was to investigate the prognostic significance of volumetric parameters measured on pretreatment FDG PET/CT scans for predicting treatment outcomes in patients with LAPC treated with CRT.

**Materials and Methods**

**Patients**

We retrospectively reviewed the medical records of all pancreatic cancer patients who underwent FDG PET/CT as part of a staging work-up prior to treatment at our institution from January 2007 to December 2010. Patients with a diagnosis of stage III biopsy-confirmed ductal adenocarcinoma, who were initially deemed surgically unresectable upon staging work-up and who received CRT, were included in this study. Sixty patients met the inclusion criteria. Baseline patient and tumor characteristics were reviewed, including age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, history of diabetes mellitus, tumor diameter (mm), tumor location, T stage, nodal status, and non-obstructive pre-CRT and post-CRT CA19-9 levels. The Institutional Review Board of our university approved this retrospective study, and the requirement to obtain informed consent was waived.

**Acquisition and analysis of FDG PET/CT scans**

All FDG PET/CT scans were performed using a dedicated PET/CT scanner (Discovery STe, GE Healthcare, Milwaukee, WI, USA or Biograph TruePoint 40, Siemens Medical Systems, CTI, Knoxville, TN, USA). All patients fasted for at least 6 h prior to the PET/CT scan. Median blood glucose level was 100 mg/dL with a range of 72–210 mg/dL. A dose of approximately 5.5 MBq/kg of FDG was intravenously injected 60 min before imaging. After the initial low-dose CT (Discovery STe: 30 mA, 130 kVp; Biograph TruePoint: 36 mA, 120 kVp), the PET scan extending from the neck to the proximal thighs with an acquisition time of 3 min per bed position in 3-D mode was performed. The PET scans were reconstructed using ordered subset expectation maximization with attenuation correction.

Volume-based assessment of the primary pancreatic cancer lesion was performed using the volume viewer software on a GE Medical Systems Advantage Workstation 4.5. Each tumor was examined with a spherical-shaped volume of interest (VOI) that included the entire lesion in the axial, sagittal, and coronal planes. The maximum SUV (SUVmax) of the VOI was calculated as (decay-corrected activity/tissue volume)/(injected dose/body weight). Once the threshold for volumetric analysis was assigned, the software automatically calculated MTV and mean SUV of the VOI from PET data by grouping all spatially connected voxels equal to or above the threshold. In this study, MTV was defined as total tumor volume with SUV ≥2.5, and TLG was calculated as (mean SUV) × MTV.

**Treatment delivery**

All 60 patients who underwent CRT received gemcitabine-
based chemotherapy. Only gemcitabine (1000 mg/m² on days 1, 8, 15, 29, and 36) was administered to most patients. Cisplatin (70 mg/m² on days 1 and 29) or capecitabine (total daily dose of 2000 mg/m² for days 1–14 and 21–35) was additionally administered to some patients depending on the preference of the responsible physicians and the general condition of the patient. Chemotherapy was withheld until the resolution of any grade 3 or 4 non-hematologic toxicity.

Patients also received conformal radiotherapy or tomotherapy as a part of CRT. According to the standard CRT protocol, patients received involved-field irradiation consisting of the gross tumor volume (GTV) with a liberal margin (2 cm). If significant lymphadenopathy was noted on the pre-treatment scans, radiotherapy of the specified lymph node areas was also performed. A median total dose of 50.4 Gy with a range of 45.0–58.4 Gy was applied with daily fractions of 1.8 Gy for 5 days per week using a 10 MV linear accelerator. After CRT, patients received maintenance gemcitabine chemotherapy (1000 mg/m² on days 1, 8, and 15, every 4 weeks) until disease progression or unacceptable toxicities occurred.

Response evaluation
All 60 enrolled patients had clinical follow-ups that included diagnostic imaging studies and blood tests. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors on contrast-enhanced CT scans obtained at 4 weeks after completion of CRT. Disease control status, defined as complete response, partial response, or stable disease, was also evaluated at each time point.

Data analysis
All 60 patients were assessed and grouped according to whether they had experienced progression of disease at the 1-year follow-up. The SUVmax, MTV, and TLG on FDG PET/CT scans, as well other tumor factors, were compared between the 2 subgroups using Mann-Whitney U tests, chi-squared tests, t-tests, and Fisher’s exact tests. Survival curves were estimated using the Kaplan-Meier method to calculate the cumulative locoregional progression-free survival (LRPFS), progression-free survival (PFS), and overall survival (OS). LRPFS was defined as survival without local or regional treatment failure, calculated as the time between the first day of treatment and the date of local or regional failure, death, or last visit. The PFS was calculated as the time between the first day of treatment and any type of disease progression, while the OS was defined as the time between the first day of treatment and the date of death or last visit.

For statistical analyses, all variables for survival were grouped into two categories according to specific cutoff values. The optimal cutoff values were determined using receiver-operating characteristic (ROC) curve analysis. The significance of the predictive value of each variable was evaluated using log-rank tests for univariate analysis and Cox proportional hazards regression tests for multivariate analysis. Multicollinearity between MTV and TLG was evaluated by calculating the Spearman rank correlation coefficient before multivariate analysis. Statistical analyses were performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). Results with p-values <0.05 were considered statistically significant.

RESULTS

Patient characteristics
Table 1 summarizes the pretreatment characteristics of all 60 patients enrolled in the study according to disease status at the 1-year follow up. The median PFS was 6.2 months [95% confidence interval (CI): 3.8–8.6 months] and the overall 1-year progression-free survival rate was 68%. Distant relapse (n=34; 82.9%) was the main cause of initial treatment failure, 31 instances of which were isolated (75.6%) and 3 (7.3%) that were concomitant with locoregional progression. Local treatment failure without concomitant distant metastasis was observed in 8 patients (19.5%), 6 (75%) of whom eventually had relapse with distant metastasis. Sites of distant metastasis included the liver (n=17), peritoneum (n=9), multiple organs (n=7), and lungs (n=1). There was no significant relationship between the pattern of initial disease progression (distant versus local) and PET/CT parameters (SUVmax, MTV, and TLG). In comparing patients with and without disease progression, SUVmax, MTV, and TLG were significantly different between these two groups (p<0.05, all) while the other demographic and clinical characteristics did not show statistical significance. From the ROC analyses, the optimal cut-off values for SUVmax, MTV, and TLG were set at 6.5, 10.0 cm³, and 45.0 g, respectively. Cut-off values for the pre-CRT CA19-9 level, post-CRT CA19-9 level, and decline in the CA19-9 levels after CRT were also defined as 646 U/mL, 144 U/mL, and 87.8%, respectively.

Tumor response assessment
Overall treatment response was 16.7% at the 4-week follow-up.
up after CRT, and the disease control rate (DCR) was 80%. To assess the predictive value of the PET/CT parameters and CA19-9 levels, we classified patients into 2 groups, higher and lower, based on the cut-off values obtained from the ROC analyses described above. There were no significant statistical differences in the PET/CT and CA19-9 results between the responder and non-responder groups. However, the DCR was significantly higher in patients whose tumors had lower SUVmax, MTV, or TLG values than those in the other group, while none of the CA19-9 parameters showed statistical differences. These results are summarized in Table 2.
Survival analysis and prognostic factors

At a median follow up of 13 months (range, 3–67 months), 58 out of the 60 evaluated patients (96.7%) had died. One patient was alive without disease progression, and the other remaining patient was also alive but had liver metastasis and peritoneal carcinomatosis. Both patients had consistently lower SUVmax, MTV, and TLG and lower pre-CRT and post-CRT CA19-9 levels, which declined significantly after CRT. During follow-up, 41 patients (68.3%) experienced some degree of treatment failure. The median durations of PFS, LRPFS, and OS were 6.2 months (95% CI: 3.8–8.6 months), 10.9 months (95% CI: 8.1–13.7 months), and 13.2 months (95% CI: 11.9–14.5 months), respectively.

Comparison of survival data using the log-rank test showed that MTV and TLG were significant prognostic indicators for PFS, LRPFS, and OS (Figs. 1 and 2), as was SUVmax for PFS and LRPFS. Through univariate analysis, pre-CRT and post-CRT CA19-9 levels were found to have prognostic significance for PFS, LRPFS, and OS. In addition, disease progression at 4 weeks after treatment was an adverse prognostic factor in terms of PFS, LRPFS, and OS. Median survival times and corresponding results of univariate analysis are shown in Table 3.

Among the significant prognostic variables found by univariate analysis, only those variables that could be assessed before treatment were included in the multivariate analysis (i.e., SUVmax, MTV, TLG, and the pre-CRT CA19-9 level). As TLG is calculated by multiplying the mean SUV and the MTV, there was a significant correlation between the MTV and TLG ($r=0.946$, $p<0.0001$). Therefore, MTV and TLG were assessed separately. On the multivariate analysis, the pre-CRT CA19-9 level and MTV were identified as independent prognostic factors for PFS, LRPFS, and OS ($p<0.05$, all) (Table 4), while TLG remained statistically significant for both LRPFS ($p=0.008$) and OS ($p=0.019$) (Table 5).

**DISCUSSION**

To date, few prognostic factors from heterogeneous study populations have been identified for LAPC. Bjerregaard, et al.\(^{21}\) reported that good performance status with small tumors was significantly associated with favorable prognosis. In a multi-center study including patients with LAPC and metastatic pancreatic cancer, the pretreatment CA19-9 level...
A decrease in the CA19-9 level (>90%) was also an independent predictor of improved median survival in a study performed by Yang, et al.\textsuperscript{23} Our analysis indicated that a pre-CRT CA19-9 level of >646 U/mL was an independent prognostic factor for poor survival in patients with LAPC who were treated with CRT, while a decline in the CA19-9 level was not. The post-CRT CA19-9 level did have statistical significance upon univariate analysis; however in the present study, it was excluded from multivariate analysis due to our focus on prognostic factors that can be as-

| Table 3. Univariate Analysis of Prognostic Factors for Survival Outcomes |
|-----------------|----------|----------|----------|
|                | PFS      | LRPS     | OS       |
|                | Median*  | p value  | Median  | p value  | Median | p value  |
| Sex            |          |          |          |
| Women          | 5.8      | 0.510    | 8.8     | 0.242    | 13.3   | 0.204    |
| Men            | 6.6      | 0.794    | 11.8    | 0.831    | 13.0   | 0.420    |
| Age (yrs)      |          |          |          |
| >65            | 6.0      | 0.913    | 9.5     | 0.95     | 9.5    | 0.13     |
| ≤65            | 5.8      | 0.626    | 12.1    | 0.626    | 13.6   | 0.725    |
| Presence of DM |          |          |          |
| Yes            | 5.8      | 0.524    | 12.2    | 0.257    | 13.2   | 0.386    |
| No             | 6.3      | 0.760    | 10.0    | 0.015    | 12.1   | 0.526    |
| ECOG performance status | |          |          |          |
| 1              | 6.2      | 0.161    | 12.1    | 0.161    | 13.2   | 0.526    |
| 0              | 3.9      | 0.161    | 7.3     | 0.161    | 8.3    | 0.526    |
| LN metastasis  |          |          |          |
| Yes            | 5.1      | 0.760    | 9.5     | 0.337    | 11.8   | 0.832    |
| No             | 6.2      | 0.524    | 10.7    | 0.015    | 13.6   | 0.526    |
| Tumor location |          |          |          |
| Head           | 6.2      | 0.566    | 12.2    | 0.161    | 13.2   | 0.526    |
| Body/tail      | 3.9      | 0.566    | 7.8     | 0.161    | 10.7   | 0.526    |
| SUVmax         |          |          |          |
| >6.5           | 3.9      | 0.015    | 7.8     | 0.028    | 9.6    | 0.172    |
| ≤6.5           | 8.5      | 0.015    | 13.1    | 0.028    | 13.3   | 0.172    |
| MTV            |          |          |          |
| >10.0 cm\textsuperscript{3} | 4.7 | 0.001    | 9.1     | 0.002    | 11.8   | 0.008    |
| ≤10.0 cm\textsuperscript{3} | 16.0 | 0.001    | 20.8    | 0.002    | 20.8   | 0.008    |
| TLG            |          |          |          |
| >45.0 g        | 4.2      | 0.017    | 8.3     | 0.003    | 9.6    | 0.007    |
| ≤45.0 g        | 9.8      | 0.017    | 14.6    | 0.003    | 16.0   | 0.007    |
| Pre-CRT CA19-9 |          |          |          |
| >646 U/mL      | 4.2      | 0.024    | 8.7     | 0.028    | 9.8    | 0.019    |
| ≤646 U/mL      | 8.5      | 0.024    | 12.2    | 0.028    | 13.6   | 0.019    |
| Post-CRT CA19-9|          |          |          |
| >144 U/mL      | 4.2      | 0.019    | 8.7     | 0.018    | 9.8    | 0.038    |
| ≤144 U/mL      | 8.6      | 0.019    | 12.2    | 0.018    | 13.6   | 0.038    |
| CA19-9 decline |          |          |          |
| >87.7%         | 6.2      | 0.212    | 10.9    | 0.305    | 13.2   | 0.109    |
| ≤87.7%         | 2.9      | 0.212    | 8.7     | 0.305    | 8.7    | 0.109    |
| Disease control status | |          |          |          |
| Progression    | 8.5      | 0.000    | 13.0    | 0.000    | 13.6   | 0.000    |
| No progression | 2.8      | 0.000    | 6.4     | 0.000    | 7.8    | 0.000    |

PFS, progression-free survival; LRPS, locoregional progression-free survival; OS, overall survival; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; LN, lymph node; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; CRT, chemoradiation therapy.

*Median survival time is expressed in months.
Several recent studies have investigated the prognostic value of FDG PET/CT results in patients with pancreatic cancer. Despite an absence of standardized cutoff values, poorer survival has consistently been associated with high SUVmax values measured on pretreatment FDG PET/CT scans of patients with primary pancreatic cancer.\(^{13-16}\) However, to the best of our knowledge, only one other study has evaluated the use of FDG PET/CT volumetric parameters for predicting clinical outcomes in patients with LAPC. In that study, Parlak, et al.\(^{20}\) used the GTV measured during radiotherapy planning as a metabolic parameter measured on FDG PET/CT volumetric parameters for predicting clinical outcomes in patients with LAPC. In this study, we evaluated the GTV measured during radiotherapy planning as a metabolic parameter measured on FDG PET/CT volumetric parameters for predicting clinical outcomes in patients with LAPC. We used a fixed SUV threshold of 2.5 and demonstrated that MTV and TLG had prognostic significances. The choice of a fixed SUV threshold of 2.5 was largely based on early studies demonstrating that an SUV within this range is optimal for differentiating between normal structures and malignant lesions and minimizes inclusion of unwanted physiological FDG uptake in normal tissues.\(^ {26-29}\) One recent study using a phantom demonstrated that an SUV of 40–50% of the maximum was appropriate for the contouring of actual tumor volume;\(^ {30}\) however, we could not clearly delineate the primary tumor from surrounding normal structures when 40–50% of the SUVmax of the tumor was applied to a threshold in several cases. In addition, it is noteworthy that suggested cutoff values to identify a favorable prognostic group vary widely by tumor site and study group. Therefore, further studies should focus on both standardization of threshold SUV and individualization of cutoff values in order to eventually integrate volumetric analysis of FDG PET/CT into clinical practices.

CRT has been regarded as a reasonable treatment option for LAPC, although the role of radiation therapy remains highly controversial. As LAPC is associated with a high rate of distant metastases and subsequent poor OS, it is now

### Table 4. Multivariate Analysis of Prognostic Factors for Survival Outcomes–Metabolic Tumor Volume Model

| Variables          | PFS          |          | LRPFS         |          | OS               |          |
|--------------------|--------------|----------|---------------|----------|------------------|----------|
|                    | HR (95% CI)  | p value  | HR (95% CI)   | p value  | HR (95% CI)      | p value  |
| Pre-CRT CA19-9     | 2.09 (1.15–3.82) | 0.016   | 1.88 (1.04–3.41) | 0.038   | 1.80 (1.01–3.21) | 0.047   |
| SUVmax             | 1.54 (0.84–2.84) | 0.165   | 1.37 (0.75–2.51) | 0.310   | 1.04 (0.57–1.89)  | 0.019   |
| MTV                | 2.21 (1.11–4.41) | 0.024   | 2.33 (1.12–4.83) | 0.023   | 2.12 (1.04–4.30)  | 0.038   |

PFS, progression-free survival; LRPFs, locoregional progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; CRT, chemoradiation therapy.

### Table 5. Multivariate Analysis of Prognostic Factors for Survival Outcomes –Total Lesion Glycolysis Model

| Variables          | PFS          |          | LRPFS         |          | OS               |          |
|--------------------|--------------|----------|---------------|----------|------------------|----------|
|                    | HR (95% CI)  | p value  | HR (95% CI)   | p value  | HR (95% CI)      | p value  |
| Pre-CRT CA19-9     | 2.21 (1.22–3.98) | 0.009   | 2.24 (1.23–4.08) | 0.008   | 2.14 (1.20–3.84) | 0.010   |
| SUVmax             | 1.69 (0.87–3.27) | 0.122   | 1.26 (0.68–2.34) | 0.466   | 0.94 (0.50–1.76)  | 0.838   |
| TLG                | 1.56 (0.82–2.98) | 0.178   | 2.41 (1.26–4.61) | 0.008   | 2.19 (1.14–4.21)  | 0.019   |

PFS, progression-free survival; LRPFs, locoregional progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SUVmax, maximum standardized uptake value; TLG, total lesion glycolysis; CRT, chemoradiation therapy.
considered as part of the spectrum of metastatic diseases. Multiple clinical trials have attempted to identify the best treatment for LAPC, and trials of only chemotherapy versus CRT have reported mixed results regarding the survival benefits of CRT; therefore, the debate continues. Recently Iacobuzio-Donahue, et al. have identified a promising biomarker, the tumor suppressor SMAD4, as a potential predictor of local versus distant disease progression. Interestingly, patients with intact SMAD4 expression had a local-dominant pattern of disease spread, while those with the loss of SMAD4 had a distant-dominant pattern. This correlation between SMAD4 expression and the pattern of disease spread has been validated by a phase II clinical trial. It has been argued that patients with occult metastatic disease or a high risk of distant metastasis might not be candidates for RT because the benefit from RT would not outweigh its side effects. In the present study, none of the PET/CT parameters that were analyzed succeeded in predicting a pattern of initial disease progression or which group of patients would show response to CRT at the 4-week follow up. However, the DCR was significantly higher in patients with lower SUVmax, MTV, or TLG, and the univariate analysis showed that the DCR was a significant prognostic indicator of survival outcomes (all \( p<0.001 \) for PFS, LR-PFS, and OS). Therefore, we postulate that the metabolic activity of pancreatic cancer lesions demonstrated on FDG PET/CT scans might be helpful to guide treatment decisions in cases of LAPC. Given the rapid disease progression and shorter survival times of patients with LAPC, RT would not be recommended when high metabolic activity is detected on pretreatment FDG PET/CT scans. As FDG PET/CT is a relatively non-invasive diagnostic tool, these metabolic parameters are more easily assessed compared to SMAD4 expression. However, a large-scale comparative study is mandatory to validate the clinical use of FDG PET/CT for predicting survival outcomes and guiding treatment decisions in patients with LAPC. There were several limitations to our study. First, as we enrolled only patients who completed full cycles of CRT and as our hospital is a tertiary referral center, those patients with poor performance and tolerability who chose to discontinue treatment or to receive palliative care at hospice centers were excluded, potentially skewing the study population to a group of better prognosis. Second, we used a threshold SUV of 2.5 for measuring the MTV of pancreatic cancer lesions. Some of the enrolled patients showed diffuse FDG uptake by the pancreatic parenchyma distal to the cancer lesion, mainly due to obstructive pancreatitis. In those patients, it was difficult to clearly differentiate tumor uptake from inflammatory uptake due to pancreatitis, which may have affected the measurement of MTV. We theorize that simultaneous anatomic correlation with other imaging modalities, such as PET-contrast-enhanced CT or PET-magnetic resonance imaging (PET/MRI) would be one solution to this problem. Third, use of different PET/CT scanners may have contributed to SUV variability to a certain extent and biased the results of the present study, although the variations of SUV among PET/CT systems in our institute were within the acceptable limit.

In conclusion, MTV measured on pretreatment FDG PET/CT scans was an independent and significant prognostic factor for predicting the PFS, LR-PFS, and OS, as was TLG for predicting the LR-PFS and OS, in patients with LAPC treated with gemcitabine-based CRT. FDG PET/CT volumetric parameters might have the potential to identify the subgroup of patients who would benefit from RT as a part of CRT.

**ACKNOWLEDGEMENTS**

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2014 (6-2014-0030).

**REFERENCES**

1. Coupland VH, Kocher HM, Berry DP, Allum W, Linklater KM, Konfortion J, et al. Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007. Cancer Epidemiol 2012;36:207-14.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993;165:68-72.
4. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002;29(6 Suppl 20):9-16.
5. Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005;23:4538-44.
6. Real FX. A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology 2003;124:1958-64.
7. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988;80:751-5.
8. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for
locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-9.

9. Klaassen DJ, Macnryte JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil—an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-8.

10. Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Borbath I, et al. Comparison of chemoradiotherapy (CRT) and chemoradiotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. Pancreatology 2013;13:S89.

11. Kaulanen SP, Komar G, Seppänen MP, Dean KI, Männ HR, Kajander SA, et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250:957-63.

12. Topkan E, Parlak C, Koteck A, Yarar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET/CT response in outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011;11:123.

13. Choi HJ, Kang CM, Lee WJ, Song SY, Cho A, Yun M, et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer. Yonsei Med J 2013;54:1377-83.

14. Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med 2011;36:331-6.

15. Hwang JP, Lim I, Chang KJ, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer. Nucl Med Mol Imaging 2012;46:207-14.

16. Moon SY, Joo KR, So YR, Lim JU, Cha JM, Shin HP, et al. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med 2013;38:778-83.

17. Fendler WP, Philippe Tiega DB, Illhan H, Paprottka PM, Heinemann V, Jakobs TF, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med 2013;54:1202-8.

18. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, et al. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging 2012;39:925-35.

19. Ryu JS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycosylation measured by 18F-FDG PET/CT in salivary gland carcinomas. J Nucl Med 2013;54:1032-8.

20. Parlak C, Topkan E, Onal C, Reyhan M, Selick U. Prognostic value of gross tumor volume delineated by FDG-PET/CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiat Oncol 2012;7:37.

21. Bjørregaard JK, Mortensen MB, Jensen HA, Nielsen M, Pfeiffer P. Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;83:909-15.

22. Haas M, Heinemann V, Kullmann F, Laubender RP, Kloze C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol 2013;139:681-9.

23. Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 2013;4:361-9.

24. Davison J, Mercier G, Russo G, Subramanium RM. PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. AJR Am J Roentgenol 2013;200:635-40.

25. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol 2013;14:1-12.

26. Van de Wiele C, Kruse V, Smeets P, Sathakege M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycosylation in solid tumours. Eur J Nucl Med Mol Imaging 2013;40:290-301.

27. Kang WJ, Chung JK, So Y, Jeong JM, Lee DS, Lee MC. Differentiation of mediastinal FDG uptake observed in patients with non-thoracice tumours. Eur J Nucl Med Mol Imaging 2004;31:202-7.

28. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-54.

29. Orlacchio A, Schillaci O, Antonelli L, D’Urso S, Sergiacomi G, Nicoli P, et al. Solitary pulmonary nodules: morphological and metabolic characterisation by FDG-PET-MDCT. Radiol Med 2011;112:157-73.

30. Uto F, Shiba E, Onoue S, Yoshimura H, Takada M, Tsujii Y, et al. Phantom study on radiotherapy planning using PET/CT—delineation of GTV by evaluating SUV. J Radiat Res 2010;51:157-64.

31. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 1981;32:164-5.

32. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemoradiotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31.

33. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-13.

34. Crane CH, Vanadhacharry GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4 (Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011;29:3037-43.

35. Park IH, Park DS, Kweon DC, Lee SB, Oh KB, Lee JD, et al. Inter-comparison of 18F-FDG PET/CT standardized uptake values in Korea. Appl Radiat Isot 2011;69:241-6.